Growth Hormone Peptides and TRH Affect Leptin and Metabolism in Critically Ill Patients | Research

The takeaway

In critically ill patients wasting muscle while gaining fat, GHRP-2 combined with TRH reduced leptin levels and improved the hormonal profile associated with the catabolic state.

Leptin reduced
Combined GHRP-2 and TRH lowered pathologically elevated leptin while reactivating the suppressed growth and thyroid hormone axes in ICU patients

What the researchers found

GHRP-2 combined with TRH infusion reduced elevated leptin levels and reactivated suppressed GH and thyroid axes in prolonged critically ill patients, addressing the paradoxical fat-gain/muscle-wasting metabolic state.

Why it matters

Muscle wasting in ICU patients dramatically increases mortality and recovery time. Correcting the underlying hormonal dysfunction with peptide therapy could preserve muscle and improve survival in this vulnerable population.

How the study worked

Randomized controlled trial in prolonged critically ill ICU patients. Continuous IV infusions of GHRP-2, TRH, and their combination were tested. Leptin, GH, IGF-1, thyroid hormones, and metabolic markers measured.

What this study cannot tell us

ICU patient population is heterogeneous. Short-term hormonal changes may not translate to improved clinical outcomes. Small study with inherent challenges of critical care research.

How to read the evidence

Moderate evidence from a randomized trial in a challenging ICU population, with clear hormonal endpoints but limited clinical outcome data.

When this study was published

Published in 1998. Research on GH secretagogues in critical illness has continued, with larger trials examining clinical outcomes.

The bigger picture

Critical illness creates complex metabolic disruption that resists conventional nutrition support. Targeting the hormonal causes of ICU wasting with specific peptides represents a fundamentally different approach to this major clinical problem.

Questions still open

Does correcting leptin and GH levels actually prevent muscle wasting in ICU patients?
What is the optimal duration of peptide therapy in critical illness?
Could early peptide intervention prevent the catabolic state from developing?

Common questions

Why do ICU patients lose muscle while gaining fat?

Critical illness suppresses growth hormone and thyroid hormones while raising cortisol and leptin. This creates a metabolic state where the body breaks down muscle for energy while storing fat, even with adequate nutrition.

Could peptide therapy save lives in the ICU?

By correcting the hormonal dysfunction that drives muscle wasting, peptide therapy could help ICU patients maintain strength for recovery. Muscle loss is a major contributor to prolonged ICU stays and death, so addressing it has significant survival implications.

Read the original research

Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.

The Journal of clinical endocrinology and metabolism, 83(9), 3062-70

View on PubMed ↗

Citation

Van den Berghe, G; Wouters, P; Carlsson, L; Baxter, R C; Bouillon, R; Bowers, C Y. (1998). Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.. The Journal of clinical endocrinology and metabolism, 83(9), 3062-70.